Skip to main content

Table 1 Baseline clinicopathologic characteristics of patients

From: Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer

   Total
N = 52 (%)
TMB high
(>  9.68 mut/Mb)
N = 26 (%)
TMB low
(≤ 9.68 mut/Mb)
N = 26 (%)
P-valuea
Age Median 65 63.5 67.5 0.18
Range 43–84 47–84 43–83
Sex Male 25 (48.1) 10 (38.5) 15 (57.7) 0.27
Female 27 (51.9) 16 (61.5) 11 (42.3)
Smoking Status Current/Former 49 (94.2) 26 (100) 23 (88.5) 0.24
Never 3 (5.8) 0 (0.0) 3 (11.5)
EGFR status Mutant 3 (5.8) 0 (0.0) 3 (11.5) 0.24
Wild type 49 (94.2) 26 (100) 23 (88.5)
Stage at Diagnosis Extensive 34 (65.4) 15 (57.7) 19 (73.1) 0.38
Limited 18 (34.6) 11 (42.3) 7 (26.9)
ECOG PS 0 7 (13.5) 3 (11.5) 4 (15.4) 0.24b
1 28 (53.8) 17 (65.4) 11 (42.3)
2 15 (28.8) 5 (19.2) 10 (38.5)
3 2 (3.8) 1 (3.8) 1 (3.8)
Response to platinum doublet Platinum sensitive 26 (50.0) 15 (57.7) 11 (42.3) 0.41c
Platinum resistant 19 (36.5) 10 (38.5) 9 (34.6)
Platinum refractory 7 (13.5) 1 (3.8) 6 (23.1)
Treatment received PD-1-monotherapyd 31 (59.6) 17 (65.4) 14 (53.8) 0.57
PD-1 + CTLA-4 21 (40.4) 9 (34.6) 12 (46.2)
Treatment setting Clinical trial 22 (42.3) 14 (53.8) 8 (30.8) 0.16
Commercial 30 (57.7) 12 (46.2) 18 (69.2)
Line of therapy 2 29 (55.8) 18 (69.2) 11 (42.3) 0.09e
3 15 (28.8) 6 (23.1) 9 (34.6)
≥ 4 8 (15.4) 2 (7.7) 6 (23.1)
Brain metastasis prior to immunotherapy Yes 17 (32.7) 7 (26.9) 10 (38.5) 0.56
No 35 (67.3) 19 (73.1) 16 (61.5)
  1. Abbreviations: ECOG PS Eastern Cooperative Oncology Group Performance Status, EGFR Epidermal growth factor receptor
  2. aP values are comparing TMB high and TMB low columns
  3. bECOG PS: 0–1 vs ≥ 2
  4. cPlatinum sensitivity: platinum sensitive vs platinum resistant/refractory
  5. dOne patient received anti PD-1 agent pembrolizumab in combination with a PIK3CA inhibitor; the remainder of patients received PD-1 monotherapy
  6. eLine of therapy: 2 vs ≥ 2